Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

BACKGROUND/AIMS: Tenofovir alafenamide (TAF) has shown less favorable effect on lipids compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis B (CHB) are scarce. Therefore, this study aimed to evaluate the effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Joonho, Shin, Jung Woo, Jung, Seok Won, Park, Eun Ji, Park, Neung Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013607/
https://www.ncbi.nlm.nih.gov/pubmed/34959261
http://dx.doi.org/10.3350/cmh.2021.0314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013607/
https://www.ncbi.nlm.nih.gov/pubmed/34959261
http://dx.doi.org/10.3350/cmh.2021.0314

Ejemplares similares